Author Topic: (AAN) PML risk cut by extending Tysabri dosing interval  (Read 231 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
(AAN) PML risk cut by extending Tysabri dosing interval
« on: April 27, 2018, 02:23:48 pm »
From Multiple Sclerosis News Today, April 23, 2018--"#AAN2018: PML Risk Cut by Extending Tysabri Dosing Interval":


https://multiplesclerosisnewstoday.com/2018/04/27/aan2018-pml-risk-cut-by-extending-tysabri-dosing-interval/
« Last Edit: May 18, 2018, 07:46:36 pm by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Medical News Today, January 7, 2019--"Biogen starts Phase 3B trial to evaluate Tysabri extended interval dosing for RRMS patients." The dosing regimen being studied would involve receiving Tysabri every 6 weeks instead of every 4 weeks.


https://multiplesclerosisnewstoday.com/2019/01/07/phase-3b-trial-tysabri-extended-interval-dosing-rrms/
« Last Edit: January 08, 2019, 03:37:39 pm by agate »
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

These researchers have found that extended interval dosing of Tysabri (every 5-8 weeks) doesn't reduce the effectiveness of the drug.

From PubMed, February 6, 2020--"Pharmacodynamics of natalizumab extended interval dosing in MS":


https://www.ncbi.nlm.nih.gov/pubmed/32019876
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

Biogen's study comparing Tysabri dosing every 4 weeks with dosing every 6 weeks apparently resulted in an 88% reduction in the risk of contracting PML with the less-frequent dosing:

From Pipeline Review (August 2, 2021), "Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis":


https://bit.ly/37edx03




MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest
More on this from Neurologylive.com (June 4, 2022), discussing a study presented at the annual CMSC meeting June 1-4, "No Significant Difference in Patient-Reported Outcomes with Natalizumab When Administered Every 6 Weeks":


https://bit.ly/3MmDeNO
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
148 Views
Last post September 28, 2016, 04:53:58 pm
by agate
0 Replies
455 Views
Last post May 16, 2017, 11:53:39 am
by agate
0 Replies
113 Views
Last post June 11, 2017, 04:49:10 pm
by agate
0 Replies
161 Views
Last post October 11, 2017, 10:47:48 am
by agate
0 Replies
24 Views
Last post December 15, 2021, 09:25:42 pm
by agate